Company news
Cann Group Ltd. (ASX:CAN) news
Cann Group Ltd. news releases on 6ix. Latest, Jul 31, 2024: Quarterly Activities Report and Appendix 4C - June 2024
Press releases — page 2
Quarterly Activities Report and Appendix 4C - June 2024
July 31, 2024
Investor Update Presentation
July 24, 2024
$1.65m Received for Sale of Equipment
July 1, 2024
Role of CEO Update
June 5, 2024
Reinstatement to Official Quotation
June 3, 2024
Update to the Q3 Appendix 4C Quarterly Cash Flow Report
June 3, 2024
Pro-forma Consolidated Statement of Financial Position
June 3, 2024
Continuation of Suspension from Quotation
May 16, 2024
Appendix 4D and Half Year Report Re-issued
May 8, 2024
Cann obtains $5M secured debt facility
May 6, 2024
Quarterly Activities Report and Appendix 4C - March 2024
April 30, 2024
Response to ASX Query
March 24, 2024
Cann receives $1.9M payment for Southern Facility assets
March 21, 2024
Resignation of CEO
March 20, 2024
Funding Update
March 18, 2024
Suspension from Quotation
February 29, 2024
Cann announces FY24 half year results
February 29, 2024
Appendix 4D & Half Year Report
February 29, 2024
Cann to defend legal proceedings brought by Rua Biosciences
February 15, 2024
Quarterly activities report and Appendix 4C - December 2023
January 30, 2024
Cann Group raises A$2m via Convertible Securities Facility
November 20, 2023
Voluntary Suspension
November 16, 2023
Quarterly activities report and Appendix 4C - September 2023
October 30, 2023
Annual General Meeting presentation
October 25, 2023
Cann to supply additional flower products to key customer
September 20, 2023
Investor Presentation - FY23 results
August 28, 2023
Cann releases FY23 results
August 27, 2023
Appendix 4E and Annual Report to shareholders
August 27, 2023
Quarterly Activities and Appendix 4C Cashflow Report
July 28, 2023
July harvest confirms Cann on track to achieve 12.5T target
July 23, 2023
Cann Group FY23 unaudited revenue results
July 4, 2023
Cann signs significant variation with key customer
June 20, 2023
Investor presentation
June 14, 2023
Cann Group half year results
February 23, 2023
S3 Trial update
January 18, 2023
Appointment of new CEO
January 9, 2023
Cann Group and Haleon sign non-binding term sheet
November 6, 2022
Amended Quarterly Activities Report
October 27, 2022
Share Purchase Plan
October 24, 2022
Chief Executive Officer role update
October 23, 2022
Scope of Mildura GMP licence extended
October 4, 2022
Cann releases FY22 results
August 28, 2022
GMP manufacturing licence granted for Mildura
June 30, 2022
Monthly Activities/Appendix 4C Cash Flow Report
April 28, 2022
New funding arrangements with National Australia Bank
April 22, 2022
ODC manufacture permit granted for Mildura
April 7, 2022
Evaluation and option agreement with GSK Consumer Healthcare
April 5, 2022
Satipharm CBD products get green light from UK FSA
March 31, 2022
Mildura facility practical completion & ODC permit granted
March 14, 2022
Cann to begin recruitment for CBD phase 3 clinical trial
February 15, 2022